LIMINATUS PHARMA INC-CL A (LIMN) Stock Income Statement
USA - NASDAQ:LIMN - US53271X1081 - Common Stock
1.17 USD
+0 (+0.43%)
1.1702 USD
+0 (+0.02%)
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 2.91M | 2.30M | 1.87M | 2.53M | 0 | |||
| Research and Development | null | null | null | null | null | |||
| Selling, General, and Administrative Expenses | null | null | null | null | null | |||
| Operating Income | -2.91M | -2.30M | -1.87M | -2.53M | 0 | |||
| Interest Income/Expense | 1.80K | 544.50K | 3.07M | 20.00K | null | |||
| Other Income/Expense | 19.00K | 566.20K | 9.59M | 7.49M | null | |||
| Non Recurring Items | null | null | 0 | -610.00K | null | |||
| Income Before Taxes | -2.89M | -1.19M | 10.79M | 4.37M | 0 | |||
| Income Tax | 18.80K | 34.00K | 539.80K | null | null | |||
| Net Income | -2.90M | -1.23M | 10.25M | 4.37M | 0 | |||
| EBITDA | undefined | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.4039 | -0.153 | 0.2977 | 0.13 | 0 | |||
| Non GAAP EPS | null | null | null | null | null | |||
| Statistics | ||||||||
All data in USD